All In Biotech

BLA 761235 · Genentech INC

Vabysmo

Faricimab-Svoa · Intravitreal

NovelPriority review

CDER novel approval, Jan 28, 2022: To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jan 28, 2022

Approved uses

4

Original approval plus efficacy supplements

Registered trials

47

16 Phase 3, 15 recruiting

FAERS reports

8,868

4,784 serious, 513 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2026.

VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.3 ) 1.1 Neovascular (wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Macular Edema Following Retinal Vein Occlusion (RVO)

Mechanism: Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD, DME, and RVO. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD, DME, and RVO has yet to be established.

Therapeutic areas: Cardiovascular and metabolic · Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 9, 2026 Supplement 8 · Efficacy LetterLabel
  • Oct 26, 2023 Supplement 3 · Efficacy LetterLabel
  • Jan 27, 2023 Supplement 1 · Efficacy LabelLetter
  • Jan 28, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
  • VABYSMO · FARICIMAB-SVOA 120MG/ML · INJECTABLE, INTRAVITREAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Faricimab" as an intervention, any sponsor and status, largest first.

All 47 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,963
  • no adverse event1,970
  • retinal thickening1,471
  • visual impairment856
  • optical coherence tomography abnormal776
  • death466
  • drug ineffective380
  • eye inflammation360
  • uveitis353
  • visual acuity tests abnormal346
  • visual acuity reduced332
  • blindness275

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20193
20201
202110
2022254
2023771
20243,756
20251,735
20262,338

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vabysmo (Faricimab-Svoa)

2024 spending

$23.6M

Beneficiaries

2,074

8,421 claims

Per beneficiary

$11,395

$44,393.84 per unit

View as table
YearSpending
2020$0
2021$0
2022$3,254,757
2023$14,996,148
2024$23,633,074

Part B: Vabysmo (Faricimab-Svoa) · HCPCS J2777

2024 spending

$1.92B

Beneficiaries

172,503

792,936 claims

Per beneficiary

$11,120

2024 ASP limit $35.15 per unit

View as table
YearSpending
2020$0
2021$0
2022$169,912,032
2023$1,296,917,273
2024$1,918,151,107

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 64 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.